pPJV7630(PowderMed)(pPJV7630(PowderMed))

概要

基本信息

药物类型

DNA疫苗

别名-

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

感染皮肤和肌肉骨骼疾病泌尿生殖系统疾病

在研适应症-

非在研适应症

生殖器疱疹

原研机构

PowderMed Ltd.

在研机构-

非在研机构

PowderMed Ltd.

权益机构-

最高研发阶段终止临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 pPJV7630(PowderMed) 相关的临床试验

NCT00310271

/ Completed临床1期

A Phase I Study Assessing Safety and Tolerability of a DNA Vaccine With a DNA Encoded Immunostimulator , Administered by Particle Mediated Epidermal Delivery Using the PowderMed ND10 Delivery System in HSV-2 Seronegative Healthy Volunteers

The purpose of this study is to evaluate how well the vaccine is tolerated at sites where administrations are given and any effects it may have on subjects' wellbeing. The study will also test the ability of vaccine to cause particular immune responses in the body.

开始日期2006-04-01

申办/合作机构

PowderMed Ltd.

NCT00274300

/ Completed临床1期

A Phase I, Two-Center, Open-Label, Dose-Escalating Study to Investigate the Safety, Tolerability and Immunogenicity of pPJV7630, a Therapeutic DNA Vaccine for Herpes Simplex Virus Type 2 (HSV-2), in Patients With Recurrent Genital Herpes Caused by HSV-2

The purpose of this study is to evaluate how well the vaccine is tolerated at sites where administrations are given and any effects it may have on subjects' wellbeing. The study will also test the ability of vaccine to cause particular immune responses in the body and evaluate the effect it has on herpes outbreaks

开始日期2004-08-01

申办/合作机构

PowderMed Ltd.

100 项与 pPJV7630(PowderMed) 相关的临床结果

登录后查看更多信息

100 项与 pPJV7630(PowderMed) 相关的转化医学

登录后查看更多信息

100 项与 pPJV7630(PowderMed) 相关的专利（医药）

登录后查看更多信息

100 项与 pPJV7630(PowderMed) 相关的药物交易

登录后查看更多信息